Drug profile · INN
ethopropazine hydrochloride
PARSIDOL
ethopropazine hydrochloride (PARSIDOL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — ethopropazine hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
ethopropazine hydrochloride (PARSIDOL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Muscarinic acetylcholine receptor M1 antagonist
Primary target: Muscarinic acetylcholine receptor M1
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ethopropazine hydrochloride?
ethopropazine hydrochloride (PARSIDOL) is a muscarinic acetylcholine receptor m1 antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ethopropazine hydrochloride?
PARSIDOL is a marketed brand name for ethopropazine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ethopropazine hydrochloride?
ethopropazine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.